Riyadh Global Summit for AI in Healthcare & Biotech

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery, biomarker development. He is also the founder Deep Longevity, Inc, a global company developing a broad range of artificial intelligence-based biomarkers of aging and longevity sold to Endurance Longevity (HKEX: 0575) in 2020.
Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for the prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling.
Under his leadership, Insilico raised over $300 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions.
Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 150 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (9th annual in 2022) the world’s largest event on aging in the pharmaceutical industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Abdulgader is the digital transformation advisor at the Health Sector Transformation Program (HSTP) part of Saudi vision 2030, he has more than 16 years of extensive knowledge and experience in healthcare IT and digital health. He is holding a master’s degree in health informatics (MHI) from Dalhousie University, Halifax, Canada, In addition to his bachelor’s degree in pharmaceutical science from King Saud University, Riyadh, Saudi Arabia. Also, Almoeen is holding an EMBA from Hult International Business School. Almoeen is a Certified Digital Business Transformation Officer (CXO) and a Certified Healthcare Chief Information Officer (CHCIO) from College of Healthcare Information Management Executives (CHIME) and a Certified Professional in Healthcare Information and Management Systems (CPHIMS) from Healthcare Information and Management Systems Society (HIMSS), USA.

EMERITUS PROFESSOR OF PHYSIOLOGY, MEDICAL SCIENCES DEPT., UMM AL-QURA UNIVERSITY, MECCA.
FORMER FOUNDING HEAD, ISLAMIC BIOMEDICAL ETHICS PROGRAMME, OXFORD ACADEMY FOR ADVANCED STUDIES, UK.
FORMER FOUNDING DIRECTOR, CENTRE FOR BIOMEDICAL ETHICS, RESEARCH CENTRE OF KING FAISAL SPECIALIST HOSPITAL, RIYADH.
FORMER MEMBER OF UNESCO INTERNATIONAL BIOETHICS COMMITTEE, PARIS.
FORMER FOUNDING HEAD, BIOETHICS SECTION, KAIMRC & KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES, RIYADH.

Dr. Areej is a faculty member in the College of Engineering at Alfaisal University, and the Director of Alfaisal's AI Center and the Human-Computer Interaction (HCI) Design Lab, a multidisciplinary research and development center, specializing in emerging technologies. Her human-centered approach to developing emerging AI technologies focuses on improving everyday workflows and quality of life.
From brain-sensing to eye-tracking interactive technologies, the HCI Lab's award-winning technologies are changing the way people with disabilities work, live and learn. Through such experience, Dr. Areej has developed a deep knowledge of trends in emerging technologies, innovation ecosystems, medtech, intellectual property (IP) creation and IP commercialization. Towards this end, Dr. Areej served in the role of Executive Director of IP Enablement at the Saudi Arabian Authority for Intellectual Property (SAIP) in 2019 and led the team which spearheaded KSA’s network for WIPO’s Technology and Innovation Support Centers (TISC). Dr. Areej spent her formative years primarily in the United States and worked in the US, UK, and Saudi Arabia. She attended the George Washington University, the University of Texas, City University of London and MIT’s School of Engineering.
More recently, she joined MIT’s Ideation Lab in the School of Engineering as an Ibn Khaldun Fellow, and was an Honorary Fellow at the University of Kent’s School of Engineering and Design. She then proceeded with MIT’s Executive Education programs at the Sloan School of Management, where she focused on Innovation, Management and Leadership.
Prior to joining Alfaisal University, Dr. Areej held several leadership roles in Saudi Arabian academic institutions including King Saud University, Prince Sultan University, Princess Noura University and King Abdulaziz City for Science and Technology (KACST). She is a prolific author and keynote speaker and was awarded SAP’s Visionary Leadership award in 2015, Dell-EMC’s Envision the Future Award in 2018, and has spearheaded the Women in Data Science community in Saudi Arabia as Stanford’s WiDS Ambassador for Saudi Arabia, serving in this role since 2017. Dr. Areej currently chairs the ACM Chartered Chapter for HCI in Saudi Arabia, ACM SIGCHI and serves as the Vice Chair for Saudi Arabia’s ACM Chartered Chapter for Accessible Computing, SIGAccess.

Asif Jan is Chief Data Officer at Owkin where he is responsible for the data strategy & partnerships, federated data and machine learning platform product management, engineering and infrastructure. Before joining Owkin, Asif spent many years in industry and academia building-up and leading data organisations across local and global scale. Most recently, he was Global Head of Analytics, Personalised Healthcare at Roche Pharma, Group Head of Data Science for Neuroscience, Head of Data Science (Real-world Data) and Technology Director (Bioinformatics & Data) for Roche Diagnostics. Prior to joining Roche, Asif worked at European Space Agency(ESA) building data platform to manage & analyse astronomy data, and at CERN as part of offline computing groups enabling global distribution, management and analysis of data from Large Hadron Collider (LHC) experiment.

Andrey Bychkov, MD, PhD, FRCPath is a Director of Digital Pathology at Kameda Medical Center, Kamogawa, Japan and a Visiting Associate Professor at Nagasaki University. Dr. Bychkov graduated with an M.D. from Russia where he also completed residency training and practiced in anatomic pathology. Later, he earned a Ph.D. in molecular medicine in Nagasaki, Japan and supervised research projects at Chulalongkorn University, Thailand.
His subspecialty is thyroid pathology and he has contributed to the 2022 WHO classifications of endocrine and hematolymphoid tumors. Dr. Bychkov is actively engaged in the projects of the Asian Working Group in Thyroid Pathology, which addresses differences between Asian and western approaches to thyroid FNA and thyroid nodules in general.
Dr. Bychkov has completed the Digital Pathology Certificate Program by the NSH/DPA. Currently he is deeply involved in the development of the Kameda Digital Pathology Network, which is one the few Asian facilities successfully adopted digital pathology and AI for primary diagnosis.
Dr. Bychkov is a deputy editor for PathologyOutlines, associate editor for JPTM and Front Med, and academic editor for several international journals (PLOS One, etc.) He has published extensively and has authored about 100 journal articles and book chapters. He regularly presents at various conferences and pathology meetings, including top-ranked events, such as USCAP, IAP, IAC, and others.

Doug Ethell, Ph.D., is CEO and Founder of Leucadia Therapeutics, which combines bench science, clinical studies, and machine learning to develop new therapeutics for neurological disorders. After 20 years as an academic, he shifted to the private sector in 2017 to focus on his company’s technologies, including deep learning and mixed input approaches to assessing anatomical structures at the brain’s base. Deep learning analysis of high-resolution cone-beam CT scans revealed anatomical changes that reduce detritus clearance from the basal forebrain—one of the first areas to develop Alzheimer’s disease pathology. A clinical study of this structure in 560 subjects is now being expanded to 2,000 in the first site, with additional study sites planned for Palm Springs, Palo Alto, Vancouver, and Tokyo. Some participants from each location will become eligible to participate in clinical trials of the company’s therapeutic device, Arethusta. That intervention should permanently restore the brain’s ability to clear detritus from brain regions most susceptible to Alzheimer’s disease. “It’s one thing to tell someone they will develop Alzheimer’s disease in 5 or 10 years and another to offer them a solution,” said Dr. Ethell.

Gopal Karemore is a principal data scientist at the danish multinational pharma company. Gopal received his PhD degree in Computer Science from the University of Copenhagen, Denmark. He has substantial experience in machine learning, computer vision, and quantum computing. Before his current job, he has worked with various industries such as Philips, GE research, Siemens Corporate Research, University of Pennsylvania, Spanish National Center for Cardiovascular Research and Novo Nordisk Foundation Centers for Protein Research and Stem Cell Biology.

Dr. Geetha Manjunath is the Founder, CEO and CTO of NIRAMAI Health Analytix, and has led the company to develop a breakthrough AI solution for detecting early stage breast cancer in a non-invasive radiation-free manner. Geetha holds a PhD from IISc and management education from Kellogg’s Chicago. She comes with over 25 years of experience in IT innovation. She has proposed and led multiple AI projects at Xerox Research and Hewlett Packard India. Before starting NIRAMAI, Geetha was a Lab Director for Data Analytics Research at Xerox India. Geetha has received many international and national recognition for her innovations and entrepreneurial work, including CSI Gold Medal, BIRAC WinER Award 2018 and is also on the Forbes List of Top 20 Self-Made Women this year. Geetha is also an inventor of 16 US patents and more pending grant. She was recently awarded the Accenture Vahini Innovator of the Year Award from Economic Times and was titled as The Woman Entrepreneur of the year 2020 by Biospectrum.

Heather Leigh Flannery is the Founder and Chief Executive Officer of Equideum Health, a spin-off from ConsenSys AG effective March 2nd, 2020. ConsenSys Health rebranded to Equideum Health on January 18th, 2022. Equideum Health is a ConsenSys partner and a ConsenSys Mesh portfolio company. Heather chairs the IEEE SA Open P2418.6 Standards Development Working Group (blockchain in healthcare and life sciences), served as FY19 and FY20 Co-Chair and FY21 Chair of the global HIMSS Blockchain in Healthcare Task Force, Chairs the Healthcare Interest Group at the Enterprise Ethereum Alliance (EEA), and is an Associate Editor of the peer-reviewed journal, Frontiers Blockchain for Science. Ms. Flannery is an active consultant, advisor, and keynote speaker.

John Lewis is the Founder, Board Chair and Chief Executive Officer at Nanostics and the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta, Edmonton, Alberta. In addition to his academic work, Dr. Lewis is the co-founder of Innovascreen Inc., a successful preclinical CRO in operation since 2005, and the founder and CEO of Entos Pharmaceuticals Inc., a clinical-stage biotechnology company developing genetic medicines, incorporated in 2007. His research involves cancer diagnostics, non-invasive molecular imaging, and targeting of angiogenesis and metastasis using multivalent nanoparticles. He trained at The Scripps Research Institute in La Jolla, CA where he developed targeted molecular imaging technologies. John Lewis earned a Ph.D. in biochemistry from the University of Victoria.

Juby George-Vazé is the CEO & Chief Innovation Officer at Globex Health. Sje is a nurse with 20+ years in the industry, last decade being in the managed care with last several years being working on value based payment models, ACOs, Big Data, AI/Machine Learning and interoperability, data security, and privacy. Successfully helped start and run a Startup like division at Anthem with innovation and reached profitability in 3 yrs. She has designed the Globex Health solutions with her experience living successfully with chronic conditions.

Dr Guidoum holds a BSc, MSc and PhD degrees in Chemical Engineering from the UK. He taught at the Universitie’ de Constantine in Algeria before moving to Abu Dhabi to join Adnoc Distribution where he held several executive positions in strategy, organization, analytics and excellence. Dr. Guidoum then led ASTRO (ADWEA Strategic Transformation) at Abu Dhabi Water & Electricity Authority where he was responsible for corporate strategy and performance management.
Dr Guidoum founded Logaritm (ex-Intuitu Analytics), the first analytics startup in Dubai, which partnered with global leaders in analytics and data. Logaritm enables organizations to master their data to accelerate analytics velocity and help create competitive advantage centered around data and insights.
Dr Guidoum used statistical analysis during his PhD research to develop a statistical model to predict thermodynamic properties. He setup an analytics function in Adnoc Distribution, where he and his team modeled operations data to achieve a 35% reduction in manpower for a 3,000+ employee business unit resulting in savings of over AED 50 million per year. He spread-headed other major business improvements like forecasting, logistics optimization, SPC, etc.
He is an active speaker in the regional and international conferences.

Dr. Pierre Vigilance is a health executive with over 20 years experience in non-profits, government, academia, advisory consulting, and technology. His primary expertise is population health strategy where he couples his broad experience with an ability to create partnerships and solutions for problems experienced by populations with poor health outcomes. As the Vice-President for Population Health & Social Impact at Equideum Health, and Executive Director of the Equideum Health Foundation, Dr. Vigilance is responsible for engaging in thought and practice-based leadership for the company related to platforms, products, and partnerships that leverage blockchain and machine learning to improve community health and wellness outcomes, and advance digital literacy and technology adoption. This calls for a diverse network of partners, and with a career that has included work in the clinical, non-profit, government, academic, and advisory consulting spaces, he is well versed in multi-sector approaches to addressing health disparities.
Dr. Vigilance has held numerous positions including serving as the first Associate Dean for Public Health Practice at the MIlken Institute School of Public Health at The George Washington University; Health Commissioner for Washington D.C.; Chief Health Officer for Baltimore County; and Assistant Health Commissioner for Baltimore City. He serves corporate and nonprofit organizations as a board member and advisor to Volunteers of America National Service, The Millenium Alliance, Seam Social Labs, Community Transformation Partners, and the Community Health Design Institute. His portfolio of work, civic engagement, and lived experiences intersect to inform the cross-sector path he takes to the pursuit and maintenance of health with communities.
Dr. Vigilance holds a Bachelor’s degree in Biology from George Washington University; Doctor of Medicine and Master of Public Health degrees from The Johns Hopkins University; and was residency trained in Emergency Medicine at Howard University Hospital.

Ryan is the Global Head of Data Science Acceleration at Roche & Genentech where he leads a team of data scientists, data engineers and software developers to develop products and capabilities that enable scientific insight generation for the clinical trial portfolio. Ryan has worked for Roche since 2003 and has held multiple data science leadership roles before his current role including building and leading the personalized healthcare analytics team who generated novel insights from real world data sources including electronic medical records, omics datasets and images. Ryan also leads the Roche Advanced Analytics Network (RAAN) which is a community of over 1500 AI and machine learning enthusiasts from 40 Roche locations across the globe.

Shadab is the Head of Applied Science at G42 Healthcare. He leads a team of applied scientists and engineers at G42 to solve problems in healthcare AI, RWE, and RWD. They develop solutions for clinical care, healthcare operations, and healthcare finance from modalities such as electronic health records, genomics, medical imaging, and insurance claims, among others. In doing so, they analyze a variety of data types including structured, unstructured, time-series, longitudinal, etc., using classical and modern algorithms from machine learning and deep learning. He works with his colleagues in product management, strategy, finance, commercials, and the C-suite to find opportunities for growth in their existing areas of interest as well as expansion into new ones.
Before joining G42 Healthcare, he was a researcher at Inception Institute of AI (IIAI) in UAE, where he focused on machine learning from limited data - a topic that he continues to focus on with his team at G42 given its strong relevance to real-world healthcare problems. At IIAI, he was also one of the four lead developers of the M.S. and Ph.D. course curriculum for the inaugural class of Mohamed Bin Zayed University of AI (MBZUAI) and participated closely in the founding and accreditation of the university. Before moving to UAE, he obtained my Ph.D. from Dartmouth College in Biomedical Engineering and did a research fellowship at Harvard Medical School and Boston Children's Hospital in Radiology.

An academic, public speaker, digital health advocate, and former Massachusetts Institute of Technology (MIT) Ibn Khaldun Fellow. Dr. Alsalamah is a contributor to the healthcare sector modernization movement, digital health transformation, and policymaking for better disease detection, prevention, and treatment. Since 2020, she has been serving as a national and global digital health policy-maker at the National Health Information Center, Saudi Health Council, Riyadh, Saudi Arabia; and Strategy and Governance Unit, Department of Digital Health and Innovation, World Health Organization, Geneva, Switzerland. In addition, Dr. Alsalamah is an Assistant Professor of Healthcare Information Systems Security, College of Computer and Information Sciences, King Saud University; and a Principle Investigator, Artificial Intelligence Center, Alfaisal University to contribute to the digital health capacity building and research community.

Dr. Taghreed Justinia is the founding Regional Director IT Services, Technology & Health Informatics at King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia, where she is also Adjunct Assistant Professor of Health Informatics and Director for the Masters Health Informatics Program in the Western Region. Dr. Justinia has maintained a career in the IT field that spans almost 20 years in executive IT positions in healthcare, including senior IT roles at the Ministry of Health and the Ministry of National Guard, Health Affairs. Dr. Justinia has several international affiliations and memberships and is an International Committee Member with the T.I.G.E.R. (Technology Informatics Guiding Education Reform) Initiative. She also represented KSAU-HS in a year-long training program with the Ministry of Education’s e-Learning Pioneers Program-Leadership Track. Dr. Justinia has several publications in international peer-reviewed journals and has authored a book.

Thomas is the CEO and Co-Founder at Owkin, leading medical research and business intelligence. He is a former Assistant Professor of Clinical Onco-Hematology at Hopital Henri Mondor in Paris. Thomas is also a former member of Ari Melnick’s lab at the Weill Cornell Medical College where he co-led several projects focused on prediction of resistance to chemotherapy in B-cell lymphoma.

Sundar is a Fellow in the AI team at the World Economic Forum, where he led the co-creation of a governance framework for the use of Chatbots in healthcare.  The framework has been piloted by four global organizations. It is now being piloted in Rwanda as part of an effort to provide healthcare access to all Rwandans. Sundar represents Mitsubishi Chemical Holdings Corporation in this role at the Forum’s Centre for the Fourth Industrial Revolution. He is a seasoned technologist with research, development, P&L and executive leadership experience. With a Master’s degree in Natural Language Understanding and a PhD in Computer Vision, Sundar made numerous research contributions in robotics, neural networks, human computer interaction, virtual/augmented reality and autonomous vehicles, prior to taking leadership roles in advanced technology production facilities.  He is passionate about responsible deployment of novel technologies in societally important areas such as healthcare.

Louise Baldwin is a Solutions Director at Tamr. In her role, Louise helps assess the value of using Tamr’s human-guided machine learning technology to achieve clean, curated, complete data for companies such as AstraZeneca and Novartis. Prior to joining Tamr, she worked as an investment professional at Goldman Sachs and IFC. She has an MBA from Harvard Business School and a Masters in Public Administration in International Development from Harvard Kennedy School.